a Department of Pediatrics, Medical School , University of Pecs , Pécs , Hungary.
b Ist Department of Pediatrics , Semmelweis University , Budapest , Hungary.
Expert Opin Biol Ther. 2019 Mar;19(3):181-196. doi: 10.1080/14712598.2019.1564034. Epub 2019 Jan 11.
At present, there is a significant amount of data related to biologics used in pediatric patients with Crohn's disease. This review characterizes the different biological drugs administered in this population.
Biological therapy of CD, focusing on children, is summarized in this review. After mechanism of action and pharmacokinetics are described, mucosal healing on anti-TNF therapy, aspects of early therapy, long-term outcome and combination therapy are discussed. Moreover, loss of response and treatment optimization, as well as drug withdrawal are summarized. Subsequently, perianal disease and surgical aspects are discussed followed by safety issues. In addition, new drugs (vedolizumab, ustekinumab), cost-effectiveness and administration of biosimilars were also included.
There are significant data to characterize biological drugs administered in pediatric patients with Crohn's disease. However, head-to-head comparative studies using different biologics are missing.
目前，有大量关于用于儿童克罗恩病患者的生物制剂的数据。这篇综述描述了在该人群中使用的不同生物药物。
本文综述了针对儿童的 CD 生物治疗。在描述了作用机制和药代动力学后，讨论了抗 TNF 治疗的黏膜愈合、早期治疗的各个方面、长期结果和联合治疗。此外，还总结了应答丧失和治疗优化以及停药问题。随后，讨论了肛周疾病和手术方面，接着是安全性问题。此外，还包括了新药（vedolizumab、ustekinumab）、成本效益和生物类似药的使用。
有大量数据可以描述用于儿童克罗恩病患者的生物制剂。然而，缺乏使用不同生物制剂的头对头比较研究。
